BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Wellstar International, Inc. and TMI Imaging System Begins Marketing to Long-Term Care Facilities


1/6/2009 11:23:21 AM

HOLLAND, OH--(Marketwire - January 05, 2009) - Wellstar International, Inc. (OTCBB: WLSI), a provider of specialized diagnostic software and equipment, announced today that its wholly-owned subsidiary, Trillennium Medical Imaging ("TMI"), is ready to begin marketing its thermal imaging system to long-term care ("LTC") facilities in the United States. National statistics currently show that the incidence rate of pressure ulcers, commonly known as bed sores, is up to 28% of the population for those living in LTC facilities; with many leading experts believing the rate is even higher.

LTC facilities generally care for patients that are critically and/or terminally ill, bed-ridden, and that show higher rates of dementia; all indicators that put an individual at risk for developing a pressure ulcer. TMI's thermal imaging diagnostic device will equip care personnel at these facilities with the ability to objectively identify patterns of injury associated with the development of pressure ulcers. This kind of early detection can lead to intervention and even prevention. By identifying the tissue changes associated with the development of these wounds prior to skin breakdown, a patient can receive considerably better care by avoiding pressure ulcer occurrence altogether. When long-term care facilities can reduce the occurrence of pressure ulcers, they receive a higher rating in the pay for performance ("P4P") initiative from the Centers for Medicare & Medicaid Services ("CMS").

Utilizing TMI's thermal imaging system technology will enable an LTC facility to provide better overall patient care and significantly lower its pressure ulcer incidence rate. By having complete documentation of every skin assessment performed, an LTC facility can mostly curtail its liabilities by protecting itself against costly lawsuits.

With nearly 16,000 long-term care facilities in the United States, and an aging population that is increasing in numbers year after year, TMI has an enormous and largely untouched market to go after with its revolutionary system. TMI's marketing plan includes a program where LTC facilities can lease the equipment necessary to perform skin assessments and store the necessary data. Lease plans start at a minimal monthly fee of $2,000 per unit. This monthly fee allows for unlimited imaging, a factor that should help promote aggressive imaging/assessment programs by these facilities.

Wellstar/TMI CEO, John Antonio, commented: "We have already seen a positive response to our thermal imaging system among the LTC facilities we have been engaged with. We expect significant revenue potential within the LTC market, and the Company anticipates placing initial units within these facilities sometime within the first quarter of 2009."

The company has developed its thermal imaging system for various applications. The TMI technology and software has been approved by the FDA as an Adjunctive Diagnostic Screening Procedure for early breast cancer detection, differential diagnoses of pain dysfunctions (such as Reflex Sympathetic Dystrophy, Neuromuscular Skeletal Syndromes and neurological disorders), for the early detection of pressure ulcers, deep tissue injuries, and bedsores, as well as for orthopedic applications. The company has plans to market diagnostic systems for all of the above mentioned applications.

ABOUT WELLSTAR INTERNATIONAL, INC.:

Wellstar International, Inc., through its wholly owned operating subsidiary Trillennium Medical Imaging, Inc. (TMI), is poised to become a leading diagnostic company in the health care industry. TMI has developed and is marketing fully calibrated and functional, thermal imaging systems that utilize state-of-the-art infrared technologies and proprietary software to accurately and cost-effectively measure physiological changes in the human body. More information on the Company and its unique diagnostic software and product line is available on Wellstar's corporate Website, by visiting: www.wellstar.us.

FORWARD-LOOKING STATEMENTS:

This press release contains statements, which may constitute 'forward-looking statements' within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.


CONTACT:

Equiti-trend Advisors LLC
(800) 953-3350 Toll-Free, U.S. & Canada
(858) 436-3350 Local or International
9:30 a.m. to 5:00 p.m. EST



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->